Can Contemporary Patients with Biopsy Gleason Score 3+4 Be Eligible for Active Surveillance?

摘要

IntroductionWe analyzed whether expansion of existing active surveillance (AS) protocols to include men with biopsy Gleason score (GS) 3+4 prostate cancer (PCa) would significantly alter pathologic and biochemical outcomes of potential candidates of AS.